Nucleix secures $55M in funding for lung cancer test

Apr 6, 2021
2020 06 01 18 51 2022 Cancer Lung 400

Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.

Nucleix will use the financing to continue to advance its methylation technology and the blood-based assay. The test analyzes subtle, disease-specific changes in DNA methylation markers in patients, specifically current and former smokers.

Latest in Lung Cancer
Artificial Intelligence Lung Color Social
Invenio enrolls 1st patients in AI-based lung cancer image analysis study
August 9, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Lung Cancer Hotspot Social
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
August 25, 2023
Artificial Intelligence Ai Suit Social
Machine learning models, blood biomarkers in research predict future disease risk
June 12, 2023
Related Stories
Digital Science Lab
CLIA
Nucleix announces CLIA certification, CAP accreditation for San Diego laboratory
2019 09 16 18 27 8672 Quality Check Mark 400
Bladder Cancer
Nucleix expands EU label for bladder cancer test
2019 09 09 20 46 2283 Lung Cancer 400
Lung Cancer
Nucleix advances EpiCheck lung cancer platform
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Lung Cancer
Invenio enrolls 1st patients in AI-based lung cancer image analysis study
By LabPulse.com staff writers
Invenio Imaging has begun enrolling patients in a pivotal study of its artificial intelligence (AI)-based image analysis module for lung cancer.
August 9, 2024
Artificial Intelligence Lung Color Social
U.K. researchers get funding for lung cancer vaccine development
By Matt Limb
Researchers are working to develop a lung cancer vaccine in the U.K. with 1.7 million pounds ($2.2 million) funding from leading charities.
April 4, 2024
Lung Cancer Hotspot Social
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
By Nick Paul Taylor
Roche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.
August 25, 2023
Lung Cancer Hotspot Social
Machine learning models, blood biomarkers in research predict future disease risk
By Nick Paul Taylor
Researchers found that analyzing genomic information and blood biomarkers is more accurate and cost-effective than analyzing genomic data alone.
June 12, 2023
Artificial Intelligence Ai Suit Social
Biodesix touts cost-saving potential of pulmonary nodule tests
By LabPulse.com staff writers
Its analyses estimated cost savings in a hypothetical population of one million patients in a U.S. Medicare or commercial payer setting over a two-year timeline.
May 30, 2023
Lung Cancer2 Social
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
By Nick Paul Taylor
Researchers see a correlation between CX3CR1 expression and outcomes in NSCLC patients treated with chemo-immunotherapy.
May 15, 2023
Lung Cancer2 Social
Thermo Fisher Scientific, Pfizer collaborate to broaden NGS testing in underserved countries
By LabPulse.com staff writers
Under the agreement, Thermo Fisher will select local labs for its NGS technology, ensuring they have the infrastructure, trained staff, and quality control measures to meet industry standards to conduct NGS testing for breast and lung cancer.
May 9, 2023
Sequencing Dna Rna Social
Oncocyte prices $13.86M public offering to support test development, commercialization
By LabPulse.com staff writers
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Lung Cancer2 Social
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
By LabPulse.com staff writers
The company noted that as a result of the designation, it can expect continued guidance and prioritized reviews from the agency of an upcoming clinical trial, part of a process aimed at obtaining a pre-market approval.
January 11, 2023
Lung Cancer2 Social
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
By LabPulse.com staff writers
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
Lung Cancer Social
University of Louisville developing experimental approach for lung cancer breath test
By Jared Berberabe
A research group is leveraging measurements of volatile organic compounds and machine learning to develop a test that detects lung cancer.
December 2, 2022
Lung Cancer Hotspot Social
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
By LabPulse.com staff writers
Its Knodule ID test is a multianalyte assay with algorithmic analysis comprising seven protein biomarkers and six clinical factors.
November 21, 2022
Cancer Lung Social
Page 1 of 7
Next Page